← All trials
NCT03326921
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 23, 2018
- Primary completion
- Dec 16, 2019
- Completion date
- Oct 16, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 24
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of WashingtonLead sponsor
- University of WashingtonOverall official - principal investigator
- University of WashingtonOfficial
- PromiCell Therapeutics, Inc.Collaborator
Drugs studied
Indications studied
- Leukemia
- Myelodysplastic Syndromes
- Plasmacytoma
- Leukemia, Lymphocytic, Chronic, B-Cell
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
- Leukemia, Biphenotypic, Acute
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Leukemia, Myeloid, Chronic-Phase
- Leukemia, Myeloid, Acute
- Leukemia, Myelomonocytic, Chronic
- Neoplasm, Residual
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Leukemia, Myelomonocytic, Juvenile
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.